Vivoryon Therapeutics NV (VVY)
Euronext Amsterdam · Netherlands · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 0.886 |
|---|---|
| 52-week range | 0.854 – 1.684 |
| Return, 1 month / 3 months | −18.0% / −28.0% |
| Return, 1 year / 3 years | −45.3% / −88.5% |
| Trend | Below its 200-day average |
| RSI (14) | 18 |
| Volatility (1 year) | 39.0% |
| Worst drawdown (1 year) | -46.3% |
| Average daily value traded | 0.03M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Vivoryon Therapeutics is a biopharmaceutical company based in Germany that develops small-molecule medicines aimed at enzymes involved in disease processes. Its work centres on inhibitors of glutaminyl cyclase, with drug candidates being studied for conditions such as Alzheimer's disease and other disorders linked to inflammation and tissue scarring. The company carries out research and clinical development and works with partners and investigators to test its compounds in patients, while its pipeline is directed at areas of unmet medical need.
On this site Vivoryon Therapeutics NV appears as a stock on the Euronext Amsterdam (Netherlands), code VVY, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Vivoryon Therapeutics NV (VVY) trades on the Euronext Amsterdam in Netherlands. It last closed at EUR 0.886 on 22 October 2026.
Its price-based Market X-Ray is 16 out of 100 (a weak price profile), ranking 102 of 109 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 45.3% and over the last three months it fell 28.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Amsterdam
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 11 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -28.7% | ||
| From 52-week high | -46.3% | ||
| Momentum | 8 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -28.0% | ||
| 6-month return | -33.9% | ||
| 12-month return, skipping the last month | -33.3% | ||
| Stability (higher is calmer) | 24 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.3% | ||
| Liquidity | 24 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −10.5% |
|---|---|
| 1 month | −18.0% |
| 3 months | −28.0% |
| 6 months | −33.9% |
| 1 year | −45.3% |
| 3 years | −88.5% |
| 5 years | −95.2% |
Signals
| 50-day / 200-day average | 1.086 / 1.243 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.043 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Amsterdam; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.